Compare Mattel Inc (MAT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Revvity Inc — how do they compare? Mattel Inc trades at $15.05 (market cap $4.30B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 3× Mattel Inc's market cap, and Revvity Inc pays a 0.24% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| MAT | RVTY | |
|---|---|---|
Market Cap | $4.30B | $12.91B |
Sector | Consumer Cyclical | Technology |
52-Week High | $22.16 | $117.75 |
52-Week Low | $13.05 | $82.26 |
Enterprise Value | $6.52B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $14.76, up 0.14%, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with a 10% revenue beat but an earnings miss, reflecting margin pressure from higher costs. Valuation appears reasonable with a P/E of 11.22 and P/S of 0.84, while profitability metrics like a 7.78% net margin and 20.5% ROE remain solid. Recent news highlights growth from toy-based films and adult collectors, though competitive and cost challenges persist.
The outlook is cautiously optimistic, supported by brand strength and entertainment initiatives, but near-term earnings volatility and discretionary spending sensitivity pose risks. Analyst consensus leans Buy with a $14.00 price target, suggesting modest upside potential from current levels amid ongoing execution scrutiny.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
